HCPCS J2329: Ublituximab-xiiy Injection, 1 mg - OpenPayer

Summary & Overview

HCPCS J2329: Ublituximab-xiiy Injection, 1 mg

HCPCS Level II code J2329 represents the injectable biologic ublituximab-xiiy billed per 1 mg. As a drug-specific HCPCS code, J2329 is used on outpatient and facility claims to report the administered dose of this monoclonal antibody therapy. Accurate use of this code matters nationally because it affects medical and pharmacy benefit adjudication, provider reimbursement, and drug utilization tracking for high-cost biologics.

Key payers included in this analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for ublituximab-xiiy, typical sites of service for administration, and the billing scenarios where a per-milligram HCPCS drug code is applied. The publication also summarizes common modifiers associated with drug administration claims, outlines expected documentation elements for unit-based drug reporting, and highlights benchmark considerations for payers and providers.

This national-focused brief provides operational guidance on claim reporting and coding context, clarifies what the code denotes on service lines, and identifies areas where policy updates or payer-specific coverage rules typically affect claim processing. Data not available in the input.

AetnaBlue Cross Blue ShieldCigna HealthUnitedHealthcareMedicareJ2329HCPCS Level IIublituximab-xiiyinjectable biologicinfusion therapydrug billingpharmacy benefitoutpatient infusiondrug unit billing

Billing Code Overview

HCPCS Level II code J2329 describes the medication ublituximab-xiiy, billed per 1 mg for injection. This HCPCS entry represents the drug product and the unit of service for administration of ublituximab-xiiy.

Service type: Injectable biologic therapy

Typical site of service: Outpatient infusion center or hospital outpatient department

Clinical & Coding Specifications

Clinical Context

A typical patient is an adult with relapsing forms of multiple sclerosis (MS) who is receiving infusion therapy with ublituximab-xiiy (J2329, 1 mg increments) in an outpatient infusion center or hospital outpatient department. The clinical workflow begins with neurology consultation documenting diagnosis, prior therapy history, and eligibility for anti-CD20 monoclonal antibody treatment. Pre-infusion evaluation includes vitals, premedication orders (e.g., antihistamine, corticosteroid, antipyretic), and verification of infusion consent and drug dose. Infusion nursing prepares the drug per pharmacy compounding, confirms the billed quantity in milligrams using J2329, and administers per infusion protocol with monitoring for infusion reactions. Post-infusion observation is performed for the recommended period; adverse events are documented and coded. Typical sites of service are outpatient infusion centers, hospital outpatient departments, and oncology/infusion clinic suites. Common clinical documentation includes indication, weight and dosing calculation, lot number, administration start and stop times, pre/post vitals, and any infusion-related reactions or additional services provided.

Coding Specifications

Modifier	Description	When to Use
`00`	No modifier — standard reporting

HCPCS Level II J2471: Pantoprazole (Hikma) Injection, 40 mg

HCPCS-J0911-TAUROLIDINE-HEPARIN-CATHETER-LOCK-HEMODIALYSIS

HCPCS Level II J0911: Taurolidine-Heparin Catheter Lock for Hemodialysis

HCPCS-J1568-INTRAVENOUS-OCTAGAM-500MG-IMMUNE-GLOBULIN

HCPCS J1568: Intravenous Immune Globulin (Octagam), 500 mg

HCPCS-J0210-METHYLDOPATE-INJECTION-250MG

HCPCS J0210: Injection, Methyldopate HCl, up to 250 mg

HCPCS-J3090-TEDIZOLID-INJECTION-1MG

HCPCS Level II J3090: Injection, tedizolid phosphate, 1 mg

HCPCS-J1806-ESMOLOL-INJECTION-CRITICAL-CARE-10MG

HCPCS J1806: Esmolol Hydrochloride Injection, 10 mg

HCPCS-J1097-PHENYLEPHRINE-KETOROLAC-OPHTHALMIC-IRRIGATION

HCPCS Level II J1097: Phenylephrine and Ketorolac Ophthalmic Irrigant, 1 ml

HCPCS-J1805-ESMOLOL-10MG-INJECTION

HCPCS J1805: Esmolol Hydrochloride Injection, 10 mg

HCPCS-J7325-HYALURONAN-SYNVISC-INTRA-ARTICULAR-INJECTION

HCPCS J7325: Hyaluronan (Synvisc) for Intra-articular Injection, 1 mg

HCPCS-J0650-LEVOTHYROXINE-INJECTION-10-MCG

HCPCS Level II J0650: Injection, Levothyroxine Sodium, 10 mcg

Showing 1–10 of 991

Taxonomy Code	Specialty	Notes
207RH0000X	Neurology	Neurologists prescribe and oversee MS infusion therapy
365A00000X	Hematology/Oncology	Oncologists/infusion specialists may administer monoclonal antibody infusions in infusion centers
163W00000X	Physical Medicine & Rehabilitation	PM&R may co-manage MS patients receiving disease-modifying infusions
174400000X	Nurse Practitioner	NPs commonly manage dosing, pre/post evaluation, and may bill incident-to or under their taxonomy
363L00000X	Registered Nurse	RNs perform infusion administration and monitoring in infusion settings

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`G35`	Multiple sclerosis	Primary indication for ublituximab-xiiy in relapsing forms of MS; determines medical necessity
`G36.0`	Neuromyelitis optica	Related demyelinating disorder; may be considered in differential though therapy indications vary
`G37.9`	Demyelinating disease of central nervous system, unspecified	Used when demyelinating disease is documented but not specified; supports use of disease-modifying therapy when appropriate
`Z79.899`	Other long term (current) drug therapy	Used to indicate the patient is on chronic disease-modifying therapy regimen
`T88.7XXA`	Unspecified adverse effect of drug or medicament, initial encounter	Used if patient experiences an infusion reaction requiring documentation and coding

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`96365`	Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour	Used when the ublituximab infusion is the initial, timed therapeutic infusion encounter and is reportable per payer rules
`96366`	Intravenous infusion, each additional hour (List separately in addition to code for primary service)	Used when infusion extends beyond the initial hour and additional timed infusion reporting is appropriate
`96374`	Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); single or initial substance/drug	May be used for single or initial IV push injections if modality differs from prolonged infusion; less common for monoclonal antibody infusions which are typically timed infusions
`36415`	Collection of venous blood by venipuncture	Performed for baseline labs (CBC, CMP, JC virus testing) prior to or during treatment initiation
`94640`	Pressurized or non-pressurized inhalation treatment for acute airway obstruction (not generally related)	Data not applicable; omitted if payer disallows unrelated procedures

Note: If a payable infusion administration code is required by the payer, 96365/96366 series are commonly billed alongside the drug HCPCS J2329. Administration and infusion observation codes should be documented with start/stop times and pre/post vitals.

OpenPayer